

ACL Laboratories COVID-19 and Influenza Activity Report

Updated: Oct 17, 2021




RESPIRATORY PATHOGEN PANEL Oct 17, 2021 Positivity Rate (%)

MONTH	FLU A Total	FLU A (H1N1)	2009 (H1N1)	FLU A (H3N2)	FLU B	RSV A	RSV B	RSV Total	PARA 1	PARA 2	PARA 3	PARA 4	Corona 229E	Corona NL63	Corona OC43	Corona HKU1	Meta pneumo	Entero Rhino	ADENO	BOCA	Legionella	Chlamydia	Mycoplasma	
JAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.7	0.3	0.0	0.0	0.0	
FEB	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	6.1	0.2	0.3	0.0	0.0	0.0	
MAR	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.4	0.1	0.1	0.3	0.1	1.4	0.9	0.1	0.4	12.2	1.2	0.3	0.0	0.1	0.1	
APR	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.5	0.0	0.0	2.5	2.9	0.0	0.8	15.3	1.4	1.2	0.0	0.0	0.0	
MAY	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	3.9	0.0	0.2	1.4	3.9	0.0	0.0	14.4	1.7	1.4	0.2	0.0	0.1	
JUN	0.0	0.0	0.0	0.0	0.0	0.1	1.8	1.9	0.0	0.3	9.6	0.0	0.3	0.4	2.4	0.0	0.1	15.8	1.1	1.8	0.0	0.0	0.1	
JUL	0.0	0.0	0.0	0.0	0.0	1.0	7.2	8.2	0.1	0.5	12.9	0.0	0.1	0.4	1.4	0.0	0.5	18.9	1.6	4.4	0.4	0.0	0.0	
AUG	0.0	0.0	0.0	0.0	0.0	0.8	12.5	13.3	0.0	1.2	6.2	0.1	0.1	0.1	0.5	0.0	0.7	14.0	1.3	3.6	0.0	0.0	0.0	
SEP	0.0	0.0	0.0	0.0	0.0	0.7	10.6	11.3	0.0	0.9	1.8	0.4	0.0	0.0	0.4	0.0	0.6	23.6	0.8	4.1	0.1	0.0	0.1	
OCT	0.0	0.0	0.0	0.0	0.0	0.5	7.9	8.4	0.0	1.3	1.2	0.7	0.1	0.0	0.4	0.0	0.2	21.6	0.7	4.8	0.5	0.0	0.0	
NOV																								
DEC																								



Increased prevalence of viruses: **Rhinovirus, RSV and Boca virus**

ACL RSVAG and PCR - Pos rate (%) - Oct 17, 2021



ACL RSV PCR and EIA positivity rates remain the same

CDC Data RSV pos rate for Region 5 Chicago - (PCR – 20%↓, Antigen - 30% ↓)




Week	IL % SCVPCR	WI % SCVPCR	IL % COVAG	WI % COVAG	IL % FLUPCR	WI % FLUPCR	IL % FLUAG	WI % FLUAG	IL % RSVAG	WI % RSVAG	IL % RSVPCR	WI % RSVPCR
Oct 17	3.7	6.5	7.0	18.0	0	0	0	0	20.0	36.0	27.0	31.3
Oct 10	4.3	7.6	5.0	18.2	0	0.2	0	0	22.2	31.8	23.9	32.6
Oct 3	5.0	8.6	6.0	16.6	0	0	0	0	20.0	34.0	24.9	35.5
Sep 26	5.0	8.1	4.4	15.2	0	0	0	0	27.7	35.9	30.0	37.7
Sep 18	4.9	9.0	7.2	17.5	0	0	0	0	33.0	31.0	28.0	39.6
Sep 12	6.5	9.6	5.9	20.5	0	0	0	0	20.0	21.9	41.6	43.7
Sep 5	6.2	8.3	7.0	22.4	0	0	0	0	33.3	43.9	38.1	40.5
Aug 29	7.5	8.5	9.0	21.3	0	0	0	0	38.9	32.5	43.9	38.8
Aug 22	6.0	7.3	13.5	16.1	0	0	0	0	31.3	27.1	32.5	20.6
Aug 15	6.6	6.8	9.8	18.0	0	0	0	0	22.9	23.5	27.0	16.7
Aug 8	6.8	7.4	9.8	15.8	0	0	0	0	16.6	22.7	25.7	16.9
Aug 1	3.8	6.9	10.5	17.6	0	0	0	0	14.9	20.0	0.0	0.0



ACL RSV tests results are consistent with “atypical” RSV outbreak

ACL FLUAG and FLUPCR - Pos rate (%) - Oct 17, 2021


- IL % FLUAG
- WI % FLUAG
- IL % FLUPCR
- WI % FLUPCR




ACL COVAG and SCVPCR - Pos rate (%) - Oct 17, 2021



Oct 13, 2021 - daily COVID-19 cases in US - CDC




Oct 2, 2021 – SARS-CoV-2 circulating in the US (~99.9% % Delta variants)



US vaccination status CDC | Data as of: Oct 12, 2021



405,444,558 Vaccines Administered	
217,953,275 People who received at least one dose	188,281,747 People who are fully vaccinated*
65.6% Percentage of the US population that has received at least one dose	56.7% Percentage of the US population that has been fully vaccinated*

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, May 23, 2021 – October 9, 2021




2021-22 Influenza Season Week 40 ending Oct 09, 2021

ILI Activity Level




CSF targets positivity rate is 1.7%

ACL RMEPNL - CSF POSITIVE TARGETS - Oct 18, 2021



The most prevalent GI bacterial target are (Campy -0.6%)

ACL GPP - STOOL POS BACTERIAL TARGETS - Oct 18, 2021



The most prevalent GI viral target is – (Adeno – 0.6%)

